Conference Coverage
Conference Coverage
EADV: No cancer signal with ixekizumab
To date, ixekizumab doesn’t raise any malignancy concerns in studies in psoriasis patients.
Conference Coverage
EADV: Secukinumab shows sustained high efficacy in SCULPTURE through 3 years
Key clinical point: Three-year data from a phase III trial provide reassurance regarding the long-term safety and efficacy of secukinumab for...
Conference Coverage
EADV: Spotlight on alexithymia in psoriasis
Key clinical point: Alexithymia is strikingly common among psoriasis patients and is associated with multiple psychiatric comorbidities and...
Conference Coverage
EADV: Long-term apremilast results show what to expect for psoriasis
Patients on apremilast for moderate to severe plaque psoriasis can reasonably anticipate a 50%-plus likelihood of a PASI-75 response after 52...
Conference Coverage
EADV: Ixekizumab promising for psoriatic arthritis
Key clinical point: The IL-17A inhibitor ixekizumab appears to be dramatically effective in psoriatic arthritis as well as in psoriasis. Major...
Conference Coverage
EADV: Investigational biologic rocks psoriasis world
An investigational inhibitor of the p19 subunit of interleukin-23 is generating efficacy results never before seen in psoriasis.
Conference Coverage
EADV: Latest gruesome twosome: Psoriasis spawns renal disease
The past decade has brought a mountain of data documenting that psoriasis, a chronic inflammatory dermatosis, is associated with increased risks...
Conference Coverage
EADV: Long-term weight loss curbs psoriasis severity
Long-term weight loss by obese psoriasis patients pays dividends in terms of sustained, clinically meaningful reduction in PASI scores.
Conference Coverage
Tissue-based treatment could improve psoriatic arthritis outcomes
Conference Coverage
WCD: Look for TNF inhibitor–induced psoriasis in kids
Pediatric TNF inhibitor–induced psoriasis remains a puzzling unsolved paradox.